Adherence and Intensity of Lipid-Lowering Therapy Influences CV Risk

MONDAY, Dec. 17, 2018 -- Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk, according to a study published online Dec. 7 in JAMA Network Open. Kamlesh Khunti, M.D., from the University of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news